Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 31738396.
- Also identified by DOI 10.1093/cid/ciz1131 and PMC identifier 7768741.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
Medical subject headings
- Carbapenem-Resistant Enterobacteriaceae
- Enterobacteriaceae Infections